Because the designation of primary neuropathologic diagnosis was not blinded to the clinical syndrome, we also classified each patient as positive or negative for AD (n = 28 positive), FTLD-TDP (n = 32 positive), FTLD-tau (PSP) (n = 26 positive), FTLD-tau (CBD) (n = 19 positive), or FTLD-tau (other) (n = 12 positive) independently of whether the neuropathologic diagnosis was called primary or contributory (meaning that a patient could be positive for >1 of these). This evidence concerns the gene MAPT and Alzheimer disease.